Liminal BioSciences Announces GMS 2022 Voting Results | News

LAVAL, Quebecand CAMBRIDGE, England, June 7, 2022 / PRNewswire / – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced the voting results at its Annual General Meeting (“AGM”) held on June 6, 2022. In total, over 20,209,035 common shares, representing 65.10% votes attached to Liminal BioSciences issued and outstanding common stock.

Selection of company directors

The six (6) candidates listed in the circular have been selected as directors of the Company who will serve in their duties until the next general meeting of shareholders or until their successors are elected or appointed.

name of the nominee

for it

abstention

Voice

%

Voice

%

Simon the Best

19 983 326

98.93

215 391

1.07

Gary Bridger

20,103,612

99.53

95.105

0.47

Neil A Klompas

20,103,778

99.53

94.938

0.47

Alek Krstajic

20,010,786

99.07

187 931

0.93

Eugeniusz Siklos

20,010,808

99.07

187 908

0.47

Timothy Steven Wach

20,103,786

99.53

94.931

0.47

Appointment of auditors

PricewaterhouseCoopers LLP has been appointed as the Company’s auditors for a term ending at the next general meeting, and the Board of Directors is empowered to set the auditors’ remuneration.

Detailed voting results for the GMS 2022 are available on SEDAR atwww.sedar.comavailable and filed at the SEC wwww.sec.gov

About Liminal BioSciences Inc.

Liminal BioSciences is a clinical biopharmaceutical company focused on developing novel small molecule drugs for patients suffering from inflammatory, fibrotic and metabolic diseases using our drug discovery platform and data-driven approach. Leading candidate for the company’s small molecule product, Fezagepras, entered a Phase Ia clinical trial in the UK in May 2022 using a single escalated dose to provide comparative data with sodium phenylbutyrate, an established nitrogen scavenger, to support the development plan. In addition, the company is also currently working on a selective GPR84 antagonist and a selective OXER1 antagonist. Our GPR84 and OXER1 antagonist programs are currently in the preclinical phase.

Liminal BioSciences operates in Canada and the United Kingdom.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act 1933, as amended, and Section 21E of the Stock Exchange Act 1934, as amended. Certain forward-looking statements are identified by a term that is forward-looking. Statements that are not of a historical nature, including the terms anticipate, expect, suggest, plan, believe, intend, estimate, strive, design, should, could, could, “will”, “forecast” and other similar expressions are are designed to identify forward-looking statements. These statements include those which are relevant to Liminal BioSciences’ goals, strategies and operations, and involve risks and uncertainties. Forward-looking information includes, but is not limited to, results of expected clinical trials, analysis of data from our clinical trials, potential development of Liminal Biosciences R&D programs, characteristics of our lead drug candidate, starting time or Type preclinical and clinical research and potential therapeutic areas.

These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements, notwithstanding whether there are known or unknown risks affecting our business or if our estimates or assumptions are incorrect Factors that could cause actual results to differ materially from those described or forecasted herein include, but are not limited to, risks related to: the ability of the Company to develop, manufacture and successfully commercialize a product, candidates if this occurs; the impact of the Covid-19 pandemic on the Company’s employees, operations, clinical development, regulatory activities, and financial and other impacts on the company; availability of funding and resources to conduct research projects developmental, clinical development, operations production or commercialization activities; successful and timely initiation or completion of clinical trials; Liminal BioSciences’ ability to obtain funding or business opportunities in the pharmaceutical industry; the Company’s ability to remedy deficiencies in the Nasdaq listing and to regain compliance with the Nasdaq listing rules; uncertainties in general related to research and development, clinical trials and related regulatory reviews and approvals; and general changes in economic conditions. For a more detailed evaluation of these risks, uncertainties and other risks that could cause actual events or results to differ materially from our current expectations, please refer to the Company’s documents and reports with the US Securities and Exchange Commission and Canadian filings with agencies. securities, including its annual Form 20-F report for the year ended December 31, 2021 and other filings and reports that are filed by Liminal Biosciences from time to time. These threats may be compounded by the ongoing Covid-19 pandemic and its associated impact on Liminal BioSciences and the global economy. Accordingly, we cannot guarantee that any particular forward-looking statement will become reality. Existing and potential investors are cautioned not to rely unduly on these forward-looking statements and estimates which are only effective as of the date of this document. Except as required by applicable securities laws and regulations, we undertake no obligation to update the forward-looking statements in this press release, whether as a result of future events or otherwise, when new information becomes available.

Contact to the company: Inamdar Temple, director of investor relations and communications, s.inamdar@liminalbiosciences.com, +1 450.781.0115; Press contact: Kaitlin Gallagherkgallagher@berrypr.com, +1 212.253.8881

Selected leveraged products registered by Prometic Life Sciences Inc.With knockouts, speculative investors can disproportionately participate in price movements. Just select the leverage you want and we’ll show you the right products open to Prometic Life Sciences Inc Shs registered

The leverage must be between 2 and 20

No data

Leave a Comment